Commentary on Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series: Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ, Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH

Autor: Trump, Donald L.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2009 27(5):574-574

Presentation, location, and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder: Dhar NB, Jones JS, Reuther AM, Dreicer R, Campbell SC, Sanii K, Klein EA, Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH.

Autor: Grossman, H. Barton

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2008 26(3):333-334

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators: Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR

Autor: Trump, Donald L.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2007 25(5):445-446

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747

Autor: Eggener Scott

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 35:123

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7354a148c3a5e8b081e54b035c188ef7
https://doi.org/10.1016/j.urolonc.2016.12.021

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).

Autor: Hussain M; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Kocherginsky M; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Agarwal N; Medicine, Huntsman Cancer Institute, Salt Lake City, Utah., Adra N; Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Zhang J; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida., Paller CJ; Oncology, Johns Hopkins University, Baltimore, Maryland., Picus J; Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri., Reichert ZR; Division of Hematology/Oncology, Internal Medicine, University of Michigan, Ann Arbor, Michigan., Szmulewitz RZ; Department of Medicine, University of Chicago, Chicago, Illinois., Tagawa ST; Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York., Kuzel TM; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Bazzi LA; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Daignault-Newton S; Urology, University of Michigan, Ann Arbor, Michigan., Whang YE; Medicine, Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Dreicer R; Medicine, University of Virginia, Charlottesville, Virginia., Stephenson RD; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Rettig MB; Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, California., Shevrin D; Medical Oncology, NorthShore University Health System, Evanston, Illinois., Gerke T; The Prostate Cancer Clinical Trials Consortium, New York, New York., Chinnaiyan AM; Pathology, University of Michigan, Ann Arbor, Michigan., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 01; Vol. 30 (19), pp. 4318-4328.